Lyell Immunopharma (LYEL) Payables (2020 - 2026)
Lyell Immunopharma (LYEL) reported Payables of $5.5 million for Q1 2026, up 46.67% on a YoY basis from $3.7 million in Q1 2025, and up 89.01% sequentially from $2.9 million in Q4 2025.
Lyell Immunopharma (LYEL) Payables (2020 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 7 years of Payables data on file, last reported at $5.5 million in Q1 2026.
- For the quarter ending Q1 2026, Payables rose 46.67% year-over-year to $5.5 million; the trailing twelve-month figure through Mar 2026 stood at $5.5 million (up 46.67% YoY), and the FY2025 full-year result was $2.9 million, down 46.09% from the prior year.
- Payables improved to $5.5 million in Q1 2026, from $2.9 million in the prior quarter.
- In the past five years, Payables ranged from a high of $6.5 million in Q1 2022 to a low of $2.6 million in Q3 2025.
- A 5-year average of $4.5 million and a median of $4.4 million in 2023 frame the typical range for Payables.
- Across the five-year window, Payables tumbled 46.09% in 2025 and jumped 46.67% in 2026, its largest moves.
- Tracing LYEL's Payables over 5 years: stood at $3.9 million in 2022, then climbed by 22.98% to $4.8 million in 2023, then gained by 11.4% to $5.4 million in 2024, then plunged by 46.09% to $2.9 million in 2025, then surged by 89.01% to $5.5 million in 2026.
- Business Quant data shows LYEL's Payables at $5.5 million in Q1 2026, $2.9 million in Q4 2025, and $2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | Lyell Immunopharma | 298.14 Mn | 298.14 Mn | - | 5.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.47 Mn |
| Dec 31, 2025 | 2.89 Mn |
| Sep 30, 2025 | 2.57 Mn |
| Jun 30, 2025 | 3.38 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | 5.37 Mn |
| Sep 30, 2024 | 3.60 Mn |
| Jun 30, 2024 | 4.20 Mn |
| Mar 31, 2024 | 4.90 Mn |
| Dec 31, 2023 | 4.82 Mn |
| Sep 30, 2023 | 4.37 Mn |
| Jun 30, 2023 | 5.81 Mn |
| Mar 31, 2023 | 5.73 Mn |
| Dec 31, 2022 | 3.92 Mn |
| Sep 30, 2022 | 4.80 Mn |
| Jun 30, 2022 | 4.25 Mn |
| Mar 31, 2022 | 6.51 Mn |
| Dec 31, 2021 | 3.21 Mn |
| Sep 30, 2021 | 3.53 Mn |
| Jun 30, 2021 | 4.86 Mn |